London
· Delayed Price · Currency is GBP · Price in USD Sangamo Therapeutics Statistics
Total Valuation
LON:0R1D has a market cap or net worth of GBP 132.87 million. The enterprise value is 124.34 million.
| Market Cap | 132.87M |
| Enterprise Value | 124.34M |
Important Dates
The next estimated earnings date is Friday, May 2, 2025.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +15.62% |
| Shares Change (QoQ) | -1.93% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 218.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.88 |
| PB Ratio | 7.31 |
| P/TBV Ratio | 7.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.59 |
| EV / Sales | 2.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.31 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.34.
| Current Ratio | 1.13 |
| Quick Ratio | 1.02 |
| Debt / Equity | 1.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.45 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -185.39% and return on invested capital (ROIC) is -70.52%.
| Return on Equity (ROE) | -185.39% |
| Return on Assets (ROA) | -46.05% |
| Return on Invested Capital (ROIC) | -70.52% |
| Return on Capital Employed (ROCE) | -176.16% |
| Revenue Per Employee | 252,289 |
| Profits Per Employee | -427,499 |
| Employee Count | 183 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.94% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +56.94% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 1.19 |
| Relative Strength Index (RSI) | 49.84 |
| Average Volume (20 Days) | 104,918 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.47 |
Income Statement
In the last 12 months, LON:0R1D had revenue of GBP 46.17 million and -78.23 million in losses. Loss per share was -0.39.
| Revenue | 46.17M |
| Gross Profit | -42.91M |
| Operating Income | -78.56M |
| Pretax Income | -78.37M |
| Net Income | -78.23M |
| EBITDA | -74.48M |
| EBIT | -78.56M |
| Loss Per Share | -0.39 |
Balance Sheet
The company has 33.48 million in cash and 24.42 million in debt, giving a net cash position of 9.07 million.
| Cash & Cash Equivalents | 33.48M |
| Total Debt | 24.42M |
| Net Cash | 9.07M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.19M |
| Book Value Per Share | 0.09 |
| Working Capital | 4.70M |
Cash Flow
In the last 12 months, operating cash flow was -53.63 million and capital expenditures -213,272, giving a free cash flow of -53.84 million.
| Operating Cash Flow | -53.63M |
| Capital Expenditures | -213,272 |
| Free Cash Flow | -53.84M |
| FCF Per Share | n/a |
Margins
Gross margin is -92.94%, with operating and profit margins of -170.15% and -169.45%.
| Gross Margin | -92.94% |
| Operating Margin | -170.15% |
| Pretax Margin | -169.74% |
| Profit Margin | -169.45% |
| EBITDA Margin | -161.32% |
| EBIT Margin | -170.15% |
| FCF Margin | n/a |
Dividends & Yields
LON:0R1D does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.62% |
| Shareholder Yield | -15.62% |
| Earnings Yield | -58.88% |
| FCF Yield | -40.52% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0R1D has an Altman Z-Score of -21.79. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.79 |
| Piotroski F-Score | n/a |